ABC News and Press, AmerisourceBergen Corporation From 01/24/23

Drug distributor AmerisourceBergen ( NYSE: ABC ) is planning to rename as Cencora in an effort to boost business outside the U.S. and beyond medicine distribution, The Wall Street Journal reported. The name change for the Conshohocken, Pa.-based company is expected to go in e...

Summary As a leader in various therapeutic areas, the company's total revenue was $7,042 million in the third quarter of 2022, up 12.5% quarter-on-quarter. Gilead will be required to make royalties of 3% on future sales of Biktarvy and bictegravir-containing medicines up to the 4th quar...

Healthcare company AmerisourceBergen ( NYSE: ABC ) said it will serve as the pharmaceutical company Civica's exclusive distribution partner and provide supply chain support for the latter's products. Civica members will get the benefits of the partnership in phases throughout H1....

Starting today, global healthcare company AmerisourceBergen will serve as Civica, Inc.’s (Civica) exclusive distribution partner and provide supply chain support for Civica’s products and a best-in-class customer experience for Civica members. Through its distribution network, Ameri...

The following slide deck was published by AmerisourceBergen Corporation in conjunction with this event. For further details see: AmerisourceBergen (ABC) Presents At 41st Annual Healthcare Conference - Slideshow

Summary AmerisourceBergen caught a strong bid in the back end of FY22. Diving underneath the hood of its earnings reveals strong evidence of outsized profitability, adding to ABC's ability to create future value for shareholders. Free cash flow growth of >100% YoY, with $2.7Bn in...

Summary Finding high quality stocks that make above average returns is possible for the average investor to do using pretty simple valuation techniques. However, most of the time, the financial media doesn't talk about these stocks when they are cheap (and if they do, the tone is usuall...

Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...

Summary WBA stock got hammered yesterday following the release of Q1 FY ‘23 results, although it clawed back some of the loss during today’s market action. It is almost a cliche now, but Q1 FY ‘23 results really weren’t that bad, with WBA taking a charge of (...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...